Based VBN 0 1 2 O
on IN 0 0 12 O
its PRP$ 1 0 12 O
minimal JJ 0 1 1 O
extent NN 0 1 1 O
of IN 0 0 12 O
absorption NN 0 1 1 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
PROTOPIC NNP 0 1 UNK B-Brand
Ointment NNP 0 1 0 O
with IN 0 0 12 O
systemically RB 0 0 UNK O
administered VBN 1 1 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
occur VB 0 1 1 O
but CC 0 0 12 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
ruled VBN 1 1 12 O
out RP 0 1 12 O
. . 0 0 12 O

Formal JJ 0 1 2 O
topical JJ 0 1 6 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
PROTOPIC NNP 0 1 UNK B-Brand
Ointment NNP 0 1 0 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Some DT 0 0 2 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
erythromycin JJ 0 1 0 B-Drug
itraconazole JJ 0 1 0 B-Drug
ketoconazole NN 0 1 16 B-Drug
fluconazole JJ 0 1 0 B-Drug
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
known VBN 1 1 12 O
CYP9A9 NNP 0 0 UNK O
inhibitors NNS 1 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
widespread JJ 0 1 1 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
erythrodermic JJ 0 1 UNK O
disease NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Alcohol NNP 0 1 2 B-Drug
( ( 0 0 2 O
this DT 0 0 12 O
combination NN 0 1 1 O
may MD 0 0 1 O
make VB 0 1 12 O
you PRP 0 0 12 O
very RB 0 1 12 O
sick JJ 0 1 12 O
) ) 0 0 2 O
and CC 0 0 12 O
primaquine NN 0 1 16 B-Drug

Interactions NNS 0 1 UNK O
Interaction NNP 0 1 2 O
may MD 0 0 1 O
occur VB 0 1 1 O
with IN 0 0 12 O
Antacids NNP 0 1 UNK B-Group
Calcium NNP 0 1 7 B-Drug
supplements NNS 1 1 6 O
Cholestyramine NNP 0 1 UNK B-Drug
Choline NNP 0 1 UNK B-Drug
and CC 0 0 12 O
magnesium NN 0 1 14 B-Drug
salicylates NNS 1 1 13 I-Drug
Colestipol NNP 0 1 UNK B-Drug
Iron NNP 0 1 2 B-Drug
- : 0 0 2 O
containing VBG 1 1 1 O
drugs NNS 1 1 6 O
Laxatives VBZ 0 1 UNK B-Group
Magnesium NNP 0 1 7 B-Drug
salicylate NN 0 1 13 I-Drug
: : 0 0 2 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
potency NN 0 1 UNK O
of IN 0 0 12 O
tetracyclines NNS 1 1 13 B-Group
. . 0 0 12 O

No DT 0 0 2 O
specific JJ 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
known VBN 1 1 12 O
at IN 0 0 12 O
this DT 0 0 12 O
time NN 0 1 12 O
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
LUCENTIS NNP 0 1 UNK B-Brand
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
Vectibix NNP 0 1 UNK B-Brand
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
performed VBN 1 1 1 O
with IN 0 0 12 O
RITUXAN NNP 0 1 UNK B-Brand
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
Therapy NNP 0 1 2 O
Special NNP 0 1 2 O
care NN 0 1 12 O
should MD 0 0 12 O
be VB 0 0 12 O
exercised VBN 1 1 1 O
in IN 0 0 12 O
treating VBG 1 1 6 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
concomitant JJ 0 1 6 O
therapy NN 0 1 6 O
( ( 0 0 2 O
either CC 0 1 12 O
topically RB 0 0 14 O
or CC 0 0 12 O
systemically RB 0 0 UNK O
) ) 0 0 2 O
with IN 0 0 12 O
known VBN 1 1 12 O
photosensitizing VBG 1 1 UNK O
agents NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
anthralin JJ 0 1 UNK B-Drug
coal NN 0 1 13 B-Drug_n
tar NN 0 1 13 I-Drug_n
or CC 0 0 12 O
coal NN 0 1 13 B-Drug_n
tar NN 0 1 13 I-Drug_n
derivatives NNS 1 1 13 I-Drug_n
griseofulvin VBP 0 1 UNK B-Drug
phenothiazines NNS 1 1 UNK B-Group
nalidixic JJ 0 0 UNK B-Drug
acid RB 0 1 14 I-Drug
halogenated VBN 0 0 UNK B-Group
salicylanilides NNS 0 1 UNK I-Group
( ( 0 0 2 O
bacteriostatic JJ 0 0 UNK O
soaps NNS 1 1 13 O
) ) 0 0 2 O
sulfonamides VBP 0 1 13 B-Drug
tetracyclines NNS 1 1 13 B-Group
thiazides NNS 1 1 UNK B-Group
and CC 0 0 12 O
certain JJ 0 1 1 O
organic JJ 0 1 13 O
staining VBG 1 1 13 O
dyes NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
methylene NN 0 1 14 B-Drug_n
blue JJ 0 1 3 I-Drug_n
toluidine NN 0 1 15 B-Drug_n
blue NN 0 1 3 I-Drug_n
rose VBD 1 1 3 O
bengal JJ 0 1 UNK O
and CC 0 0 12 O
methyl JJ 0 0 13 O
orange NN 0 1 16 O
. . 0 0 12 O

In IN 0 0 2 O
controlled JJ 0 1 1 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
ALOXI NNP 0 1 UNK B-Brand
injection NN 0 1 3 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
safely RB 0 0 UNK O
administered VBN 1 1 1 O
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
analgesics NNS 1 1 14 B-Group
antiemetics NNS 1 1 14 B-Group
/ JJ 0 0 2 O
antinauseants NNS 0 0 UNK B-Group
antispasmodics NNS 1 1 UNK B-Group
and CC 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
. . 0 0 12 O

Palonosetron NNP 0 1 UNK B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
antitumor NN 0 1 UNK O
activity NN 0 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
five CD 0 1 12 O
chemotherapeutic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
tested VBN 1 1 1 O
( ( 0 0 2 O
cisplatin JJ 0 1 14 B-Drug
cyclophosphamide NN 0 1 14 B-Drug
cytarabine NN 0 1 13 B-Drug
doxorubicin NN 0 1 13 B-Drug
and CC 0 0 12 O
mitomycin VB 0 1 13 B-Drug
C NNP 0 0 2 I-Drug
) ) 0 0 2 O
in IN 0 0 12 O
murine NN 0 1 13 O
tumor NN 0 1 6 O
models NNS 1 1 UNK O
. . 0 0 12 O

Palonosetron NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
eliminated VBN 1 1 UNK O
from IN 0 0 12 O
the DT 0 0 12 O
body NN 0 1 3 O
through IN 0 0 12 O
both DT 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
and CC 0 0 12 O
metabolic JJ 0 1 6 O
pathways NNS 1 1 13 O
with IN 0 0 12 O
the DT 0 0 12 O
latter JJ 0 0 UNK O
mediated VBD 1 1 13 O
via IN 0 0 1 O
multiple JJ 0 1 1 O
CYP NNP 0 1 UNK O
enzymes NNS 1 1 14 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicated VBD 1 1 1 O
that IN 0 0 12 O
palonosetron NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
an DT 0 0 12 O
inhibitor NN 0 1 14 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
CYP9A9 NNP 0 0 UNK O
CYP9B9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9E9 NNP 0 0 UNK O
and CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
/ NNP 0 0 2 O
9 CD 0 0 2 O
( ( 0 0 2 O
CYP9C9 NNP 0 0 UNK O
was VBD 1 0 12 O
not RB 0 1 12 O
investigated VBN 1 1 1 O
) ) 0 0 2 O
nor CC 0 0 12 O
does VBZ 1 0 12 O
it PRP 0 0 12 O
induce VB 0 1 6 O
the DT 0 0 12 O
activity NN 0 1 1 O
of IN 0 0 12 O
CYP9A9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
/ $ 0 0 2 O
9 CD 0 0 2 O
. . 0 0 12 O

Therefore RB 0 0 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
palonosetron NN 0 1 UNK B-Drug
appears VBZ 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
low JJ 0 1 1 O
. . 0 0 12 O

Potential JJ 0 1 UNK O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
OXISTAT NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Although IN 0 0 12 O
no DT 0 0 12 O
drug NN 0 1 1 O
/ VBZ 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
discovered VBN 1 1 12 O
during IN 0 0 12 O
the DT 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
of IN 0 0 12 O
MARINOL NNP 0 1 UNK B-Brand
Capsules NNP 0 1 0 O
cannabinoids NNS 0 1 UNK B-Group
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
through IN 0 0 12 O
both DT 0 0 12 O
metabolic JJ 0 1 6 O
and CC 0 0 12 O
pharmacodynamic JJ 0 1 UNK O
mechanisms NNS 1 1 UNK O
. . 0 0 12 O

Two CD 0 1 2 O
early JJ 0 1 12 O
clinical JJ 0 1 6 O
studies NNS 1 1 1 O
conducted VBN 1 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
received VBD 1 1 12 O
Macugen NNP 0 1 UNK B-Brand
alone RB 0 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
PDT NNP 0 1 UNK O
revealed VBD 1 1 12 O
no DT 0 0 12 O
apparent JJ 0 1 1 O
difference NN 0 1 UNK O
in IN 0 0 12 O
the DT 0 0 12 O
plasma NN 0 1 14 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
pegaptanib NN 0 1 UNK B-Drug
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
Dronabinol NNP 0 1 UNK B-Drug
: : 0 0 2 O
In IN 0 0 2 O
studies NNS 1 1 1 O
involving VBG 1 1 1 O
patients NNS 1 1 6 O
with IN 0 0 12 O
AIDS NNP 0 1 6 O
and CC 0 0 12 O
/ NNP 0 0 2 O
or CC 0 0 12 O
cancer NN 0 1 6 O
MARINOL NNP 0 1 UNK B-Brand
( ( 0 0 2 O
Dronabinol NNP 0 1 UNK B-Drug
) ) 0 0 2 O
Capsules NNP 0 1 0 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
co VBN 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
a DT 0 0 12 O
variety NN 0 1 1 O
of IN 0 0 12 O
medications NNS 1 1 6 O
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
cytotoxic NN 0 1 UNK O
agents NNS 1 1 1 O
anti VBP 0 0 3 B-Drug
- : 0 0 2 O
infective JJ 0 0 13 I-Drug
agents NNS 1 1 1 O
sedatives VBZ 0 1 6 B-Group
or CC 0 0 12 O
opioid JJ 0 1 13 B-Group
analgesics NNS 1 1 14 I-Group
) ) 0 0 2 O
without IN 0 0 12 O
resulting VBG 1 1 1 O
in IN 0 0 12 O
any DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
/ NNP 0 0 2 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
. . 0 0 12 O

The DT 0 0 2 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
known JJ 0 1 12 O
CYP9A NNP 0 0 UNK O
family NN 0 1 12 O
of IN 0 0 12 O
inhibitors NNS 1 1 14 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
widespread JJ 0 1 1 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
erythrodermic JJ 0 1 UNK O
disease NN 0 1 6 O
should MD 0 0 12 O
be VB 0 0 12 O
done VBN 1 0 12 O
with IN 0 0 12 O
caution NN 0 0 1 O
. . 0 0 12 O

Some DT 0 0 2 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
such JJ 0 0 1 O
drugs NNS 1 1 6 O
are VBP 1 0 12 O
erythromycin JJ 0 1 0 B-Drug
itraconazole JJ 0 1 0 B-Drug
ketoconazole NN 0 1 16 B-Drug
fluconazole JJ 0 1 0 B-Drug
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
cimetidine NN 0 1 13 B-Drug
. . 0 0 12 O

Potential JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
Elidel NNP 0 1 UNK B-Brand
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
immunizations NNS 1 1 6 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
very RB 0 1 12 O
low JJ 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
of IN 0 0 12 O
pimecrolimus NN 0 1 13 B-Drug
detected VBN 1 1 1 O
in IN 0 0 12 O
some DT 0 0 12 O
patients NNS 1 1 6 O
after IN 0 0 12 O
topical JJ 0 1 6 O
application NN 0 1 1 O
systemic JJ 0 1 6 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
but CC 0 0 12 O
can MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
ruled VBN 1 1 12 O
out RP 0 1 12 O
. . 0 0 12 O

Since IN 0 1 2 O
there EX 0 0 12 O
is VBZ 1 0 12 O
no DT 0 0 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
theophylline JJ 0 1 16 B-Drug
interaction NN 0 1 UNK O
with IN 0 0 12 O
other JJ 0 0 12 O
methylxanthines NNS 0 1 UNK B-Group
such JJ 0 0 1 O
as IN 1 0 12 O
caffeine NN 0 1 6 B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
. . 0 0 12 O

However RB 0 0 1 O
renal JJ 0 1 6 O
toxicity NN 0 1 6 O
was VBD 1 0 12 O
seen VBN 1 1 12 O
with IN 0 0 12 O
this DT 0 0 12 O
drug NN 0 1 1 O
in IN 0 0 12 O
combination NN 0 1 1 O
with IN 0 0 12 O
cisplatin NN 0 1 14 B-Drug
in IN 0 0 12 O
clinical JJ 0 1 6 O
trials NNS 1 1 1 O
. . 0 0 12 O

Digoxin NN 0 1 0 B-Drug
: : 0 0 2 O
Sparfloxacin NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
. . 0 0 12 O

Methylxanthines NNS 0 1 UNK B-Group
: : 0 0 2 O
Sparfloxacin NN 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
plasma NN 0 1 14 O
theophylline JJ 0 1 16 B-Drug
concentrations NNS 1 1 13 O
. . 0 0 12 O

Although IN 0 0 12 O
this DT 0 0 12 O
displacement NN 0 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
confirmed VBN 1 1 12 O
in IN 0 0 12 O
vivo NN 0 1 13 O
practitioners NNS 1 1 UNK O
should MD 0 0 12 O
monitor VB 0 1 1 O
patients NNS 1 1 6 O
for IN 0 0 12 O
a DT 0 0 12 O
change NN 0 1 1 O
in IN 0 0 12 O
dosage NN 0 1 0 O
requirements NNS 1 1 1 O
when WRB 0 0 12 O
administering VBG 1 1 1 O
dronabinol NN 0 1 16 B-Drug
to TO 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
other JJ 0 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Dronabinol NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
highly RB 0 1 1 O
protein JJ 0 1 14 O
bound NN 0 1 12 O
to TO 0 0 12 O
plasma VB 0 1 14 O
proteins NNS 1 1 14 O
and CC 0 0 12 O
therefore RB 0 0 1 O
might MD 0 0 12 O
displace VB 0 0 13 O
other JJ 0 0 12 O
protein NN 0 1 14 O
- : 0 0 2 O
bound NN 0 1 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Cimetidine NN 0 1 0 B-Drug
: : 0 0 2 O
Cimetidine NN 0 1 0 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
affect VB 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
sparfloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

The DT 0 0 2 O
oral JJ 0 1 6 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
sparfloxacin NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
reduced VBN 1 1 1 O
when WRB 0 0 12 O
the DT 0 0 12 O
aluminum NN 0 1 16 B-Drug
- : 0 0 2 O
magnesium NN 0 1 14 B-Drug
suspension NN 0 1 3 O
is VBZ 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
sparfloxacin JJ 0 1 UNK O
administration NN 0 1 1 O
. . 0 0 12 O

Zinc NNP 0 1 2 B-Drug
/ NNP 0 0 2 O
iron NN 0 1 3 B-Drug
salts NNS 1 1 13 O
: : 0 0 2 O
Absorption NN 0 1 UNK O
of IN 0 0 12 O
quinolones NNS 0 1 13 B-Group
is VBZ 1 0 12 O
reduced VBN 1 1 1 O
significantly RB 0 0 1 O
by IN 0 0 12 O
these DT 0 0 12 O
preparations NNS 1 1 13 O
. . 0 0 12 O

These DT 0 0 1 O
products NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
taken VBN 1 1 12 O
9 CD 0 0 2 O
hours NNS 1 1 12 O
after IN 0 0 12 O
sparfloxacin JJ 0 1 UNK B-Drug
administration NN 0 1 1 O
. . 0 0 12 O

Probenecid NN 0 1 UNK B-Drug
: : 0 0 2 O
Probenecid NN 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
sparfloxacin NN 0 1 UNK B-Drug
. . 0 0 12 O

However RB 0 0 1 O
because IN 0 0 12 O
telbivudine NN 0 1 13 B-Drug
is VBZ 1 0 12 O
eliminated VBN 1 1 UNK O
primarily RB 0 0 1 O
by IN 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
co NN 0 1 12 O
administration NN 0 1 1 O
of IN 0 0 12 O
telbivudine NN 0 1 13 B-Drug
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
alter VBP 0 1 13 O
renal JJ 0 1 6 O
function NN 0 1 1 O
may MD 0 0 1 O
alter VB 0 1 13 O
plasma JJ 0 1 14 O
concentrations NNS 1 1 13 O
of IN 0 0 12 O
telbivudine NN 0 1 13 B-Drug
. . 0 0 12 O

Telbivudine NN 0 1 UNK B-Drug
is VBZ 1 0 12 O
excreted VBN 1 1 UNK O
mainly RB 0 0 1 O
by IN 0 0 12 O
passive JJ 0 1 1 O
diffusion NN 0 1 1 O
so IN 0 1 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
for IN 0 0 12 O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
telbivudine NN 0 1 13 B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
eliminated VBN 1 1 UNK O
by IN 0 0 12 O
renal JJ 0 1 6 O
excretion NN 0 1 14 O
is VBZ 1 0 12 O
low JJ 0 1 1 O
. . 0 0 12 O

Caution NN 0 0 UNK O
is VBZ 1 0 12 O
indicated VBN 1 1 1 O
when WRB 0 0 12 O
Aredia NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
used VBN 1 1 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
potentially RB 0 0 1 O
nephrotoxic JJ 0 1 UNK O
drugs NNS 1 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
furosemide NN 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
administered VBN 1 1 1 O
in IN 0 0 12 O
intravenous JJ 0 1 14 O
lines NNS 1 1 3 O
containing VBG 1 1 1 O
PRIMACOR NNP 0 1 UNK B-Brand
. . 0 0 12 O

Chemical NNP 0 1 UNK O
Interactions NNP 0 1 UNK O
There EX 0 0 12 O
is VBZ 1 0 12 O
an DT 0 0 12 O
immediate JJ 0 1 1 O
chemical NN 0 1 13 O
interaction NN 0 1 UNK O
which WDT 0 0 12 O
is VBZ 1 0 12 O
evidenced VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
formation NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
precipitate NN 0 1 13 O
when WRB 0 0 12 O
furosemide NN 0 1 0 B-Drug
is VBZ 1 0 12 O
injected VBN 1 1 3 O
into IN 0 0 12 O
an DT 0 0 12 O
intravenous JJ 0 1 14 O
line NN 0 1 12 O
of IN 0 0 12 O
an DT 0 0 12 O
infusion NN 0 1 14 O
of IN 0 0 12 O
PRIMACOR NNP 0 1 UNK B-Brand
. . 0 0 12 O

May NNP 0 1 2 O
interact NN 0 0 UNK O
with IN 0 0 12 O
cimetidine NN 0 1 13 B-Drug
digoxin NN 0 1 14 B-Drug
medicines NNS 1 1 6 O
to TO 0 0 12 O
control VB 0 1 1 O
heart NN 0 1 12 O
rhythm NN 0 1 3 O
sevelamer NN 0 1 16 B-Drug
and CC 0 0 12 O
theophylline NN 0 1 16 B-Drug
. . 0 0 12 O

The DT 0 0 2 O
interaction NN 0 1 UNK O
may MD 0 0 1 O
result VB 0 1 1 O
from IN 0 0 12 O
reduced JJ 0 1 1 O
absorption NN 0 1 1 O
of IN 0 0 12 O
phenytoin NN 0 1 16 B-Drug
and CC 0 0 12 O
an DT 0 0 12 O
increase NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
rate NN 0 1 1 O
of IN 0 0 12 O
its PRP$ 1 0 12 O
metabolism NN 0 1 16 O
and CC 0 0 12 O
elimination NN 0 1 UNK O
. . 0 0 12 O

captopril NN 0 1 0 B-Drug
; : 0 0 2 O

chlorthalidone NN 0 1 13 B-Drug
furosemide NN 0 1 0 B-Drug
hydrochlorothiazide IN 0 1 0 B-Drug
spironolactone NN 0 1 0 B-Drug
; : 0 0 2 O

and CC 0 0 12 O
potassium NN 0 1 14 B-Drug
supplements NNS 1 1 6 O
. . 0 0 12 O

heparin NN 0 1 14 B-Drug
warfarin NN 0 1 14 B-Drug
diazepam JJ 0 1 0 B-Drug
insulin NN 0 1 14 B-Drug
; : 0 0 2 O

Twelve NNP 0 1 UNK O
of IN 0 0 12 O
9 CD 0 0 2 O
( ( 0 0 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
) ) 0 0 2 O
patients NNS 1 1 6 O
developed VBD 1 0 1 O
serious JJ 0 1 12 O
intraocular JJ 0 1 13 O
inflammation NN 0 1 6 O
; : 0 0 2 O

in IN 0 0 12 O
9 CD 0 0 2 O
of IN 0 0 12 O
the DT 0 0 12 O
9 CD 0 0 2 O
patients NNS 1 1 6 O
this DT 0 0 12 O
occurred VBD 1 1 1 O
when WRB 0 0 12 O
LUCENTIS NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
administered VBN 1 1 1 O
9 CD 0 0 2 O
days NNS 1 1 12 O
( ( 0 0 2 O
9 CD 0 0 2 O
days NNS 1 1 12 O
) ) 0 0 2 O
after IN 0 0 12 O
verteporfin NN 0 1 UNK B-Drug
PDT NNP 0 1 UNK O
. . 0 0 12 O

isosorbide JJ 0 1 16 B-Drug
dinitrate NN 0 0 0 I-Drug
nitroglycerin NN 0 1 14 B-Drug
; : 0 0 2 O

hydralazine NN 0 1 14 B-Drug
prazosin NN 0 1 16 B-Drug
; : 0 0 2 O

- : 0 0 2 O
Antacids NNS 0 1 UNK B-Group
- : 0 0 2 O
Diarrhea NNP 0 1 7 O
medicine NN 0 1 6 O
containing VBG 1 1 1 O
kaolin NN 0 1 13 B-Drug
or CC 0 0 12 O
attapulgite JJ 0 1 UNK B-Drug
- : 0 0 2 O
Ketoconazole NNP 0 1 UNK B-Drug
- : 0 0 2 O
Central NNP 0 1 2 B-Group
nervous JJ 0 1 6 I-Group
system NN 0 1 1 I-Group
CNS NNP 0 1 6 I-Group
depressants NNS 1 0 13 I-Group
- : 0 0 2 O
Other JJ 0 0 2 O
anticholinergics NNS 1 1 13 B-Group
- : 0 0 2 O
Tricyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Elavil NNP 0 1 0 B-Brand
Asendin NNP 0 1 UNK B-Brand
Anafranil NNP 0 1 UNK B-Brand
Pertofrane NNP 0 1 UNK B-Brand
Sinequan NNP 0 1 0 B-Brand
Tofranil NNP 0 1 0 B-Brand
Aventyl NNP 0 1 UNK B-Brand
Surmontil NNP 0 1 UNK B-Brand
) ) 0 0 2 O
- : 0 0 2 O
Potassium NN 0 1 14 B-Drug
chloride NN 0 1 14 I-Drug
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
Kay NNP 0 0 19 B-Brand
Ciel NNP 0 0 13 I-Brand
) ) 0 0 2 O

Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Pirenzepine NN 0 1 UNK B-Drug
may MD 0 0 1 O
interact VB 0 0 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
following VBG 1 1 1 O
drugs NNS 1 1 6 O
which WDT 0 0 12 O
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
Pirenzepine NNP 0 1 UNK B-Drug
or CC 0 0 12 O
whose WP$ 0 0 12 O
effects NNS 1 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
. . 0 0 12 O

Consult VB 0 1 UNK O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
or CC 0 0 12 O
pharmacist NN 0 1 13 O
if IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
any DT 0 0 12 O
of IN 0 0 12 O
the DT 0 0 12 O
following NN 0 1 1 O
: : 0 0 2 O
seizure NN 0 1 6 O
medications NNS 1 1 6 O
antibiotics NNS 1 1 6 B-Group
warfarin VBP 0 1 14 B-Drug
medications NNS 1 1 6 O
to TO 0 0 12 O
help VB 0 1 12 O
you PRP 0 0 12 O
sleep VB 0 1 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interaction NN 0 1 2 O
: : 0 0 2 O
The DT 0 0 2 O
concomitant NN 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
anticholinergic JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
may MD 0 0 1 O
make VB 0 1 12 O
patients NNS 1 1 6 O
hyporesponsive JJ 0 0 UNK O
i.e NN 0 1 16 O
. . 0 0 12 O

may MD 0 0 1 O
produce VB 0 0 1 O
a DT 0 0 12 O
false JJ 0 1 13 O
positive JJ 0 1 1 O
result NN 0 1 1 O
. . 0 0 12 O

Talk NN 0 1 UNK O
to TO 0 0 12 O
your PRP$ 0 0 12 O
pharmacist NN 0 1 13 O
for IN 0 0 12 O
more JJR 0 1 12 O
information NN 0 1 1 O
. . 0 0 12 O

Drug NN 0 1 2 O
Interactions NNP 0 1 UNK O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
- : 0 0 2 O
This DT 0 0 2 O
medicine NN 0 1 6 O
may MD 0 0 1 O
be VB 0 0 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
drug NN 0 1 1 O
cholestyramine NN 0 1 13 B-Drug
and CC 0 0 12 O
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
taken VBN 1 1 12 O
with IN 0 0 12 O
any DT 0 0 12 O
form NN 0 1 1 O
of IN 0 0 12 O
estrogen NN 0 1 6 O
therapy NN 0 1 6 O
. . 0 0 12 O

If IN 0 0 12 O
you PRP 0 0 12 O
are VBP 1 0 12 O
taking VBG 1 0 12 O
these DT 0 0 12 O
medicines NNS 1 1 6 O
together RB 0 1 12 O
or CC 0 0 12 O
you PRP 0 0 12 O
have VBP 0 0 12 O
further JJ 0 1 1 O
questions NNS 1 1 12 O
about IN 0 1 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
talk VBP 0 1 12 O
to TO 0 0 12 O
your PRP$ 0 0 12 O
doctor NN 0 1 12 O
or CC 0 0 12 O
pharmacist NN 0 1 13 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
this DT 0 0 12 O
medicine JJ 0 1 6 O
include NN 0 1 1 O
: : 0 0 2 O
Rifampin NNP 0 1 0 B-Drug
barbiturates VBZ 0 1 14 B-Group
phenytoin FW 0 1 16 B-Drug
( ( 0 0 2 O
Dilantin NNP 0 1 0 B-Brand
) ) 0 0 2 O
carbamazepine NN 0 1 16 B-Drug
( ( 0 0 2 O
Tegretol NNP 0 1 0 B-Brand
) ) 0 0 2 O
Estrogens NNP 0 1 0 B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
benzodiazepines NNS 1 1 14 B-Group
( ( 0 0 2 O
lorezepam JJ 0 0 UNK B-Drug
oxezepam RB 0 0 UNK B-Drug
temezepam NN 0 0 UNK B-Drug
) ) 0 0 2 O
. . 0 0 12 O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
formal JJ 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
of IN 0 0 12 O
PHOTOFRIN NNP 0 1 UNK B-Brand
and CC 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
photosensitizing VBG 1 1 UNK B-Group
agents NNS 1 1 1 I-Group
( ( 0 0 2 O
e.g. JJ 0 0 UNK O
tetracyclines NNS 1 1 13 B-Group
sulfonamides NNS 1 1 13 B-Group
phenothiazines NNS 1 1 UNK B-Group
sulfonylurea VBP 0 1 UNK B-Group
hypoglycemia NN 0 1 6 O
agents NNS 1 1 1 O
thiazide IN 0 1 UNK B-Group
diuretics NNS 1 1 14 I-Group
and CC 0 0 12 O
griseofulvin NN 0 1 UNK B-Drug
) ) 0 0 2 O
could MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
photosensitivity NN 0 1 UNK O
reaction NN 0 1 1 O
. . 0 0 12 O

PHOTOFRIN NNP 0 1 UNK B-Brand
PDT NNP 0 1 UNK O
causes VBZ 1 1 6 O
direct JJ 0 1 1 O
intracellular JJ 0 1 UNK O
damage NN 0 1 1 O
by IN 0 0 12 O
initiating VBG 1 1 1 O
radical JJ 0 1 1 O
chain NN 0 1 16 O
reactions NNS 1 1 1 O
that WDT 0 0 12 O
damage VBP 0 1 1 O
intracellular JJ 0 1 UNK O
membranes NNS 1 1 6 O
and CC 0 0 12 O
mitochondria NNS 1 1 UNK O
. . 0 0 12 O

Tissue NN 0 1 7 O
damage NN 0 1 1 O
also RB 0 0 12 O
results NNS 1 1 1 O
from IN 0 0 12 O
ischemia JJ 0 1 8 O
secondary JJ 0 1 1 O
to TO 0 0 12 O
vasoconstriction VB 0 1 UNK O
platelet NN 0 1 14 O
activation NN 0 1 13 O
and CC 0 0 12 O
aggregation NN 0 1 UNK O
and CC 0 0 12 O
clotting NN 0 1 14 O
. . 0 0 12 O

Research NN 0 1 UNK O
in IN 0 0 12 O
animals NNS 1 1 12 O
and CC 0 0 12 O
in IN 0 0 12 O
cell NN 0 1 1 O
culture NN 0 1 1 O
has VBZ 1 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
many JJ 0 0 12 O
drugs NNS 1 1 6 O
could MD 0 0 12 O
influence VB 0 0 UNK O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
PDT NNP 0 1 UNK O
possible JJ 0 1 1 O
examples NNS 1 1 UNK O
of IN 0 0 12 O
which WDT 0 0 12 O
are VBP 1 0 12 O
described VBN 1 1 1 O
below IN 0 0 12 O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
no DT 0 0 12 O
human JJ 0 1 1 O
data NNS 0 1 1 O
that WDT 0 0 12 O
support NN 0 1 1 O
or CC 0 0 12 O
rebut VB 0 0 UNK O
these DT 0 0 12 O
possibilities NNS 1 1 1 O
. . 0 0 12 O

Compounds NNS 0 1 UNK O
that WDT 0 0 12 O
quench VBP 0 0 UNK O
active JJ 0 1 1 O
oxygen NN 0 1 3 O
species NNS 1 1 1 O
or CC 0 0 12 O
scavenge NN 0 0 UNK O
radicals NNS 1 1 UNK O
such JJ 0 0 1 O
as IN 1 0 12 O
dimethyl NN 0 0 UNK B-Drug_n
sufloxide NN 0 0 UNK I-Drug_n
b SYM 0 0 16 B-Drug
- : 0 0 2 O
carotene NN 0 1 UNK I-Drug
ethanol JJ 0 1 1 B-Drug
formate NN 0 1 UNK B-Drug_n
and CC 0 0 12 O
mannitol NN 0 1 14 B-Drug
would MD 0 0 12 O
be VB 0 0 12 O
expected VBN 1 1 12 O
to TO 0 0 12 O
decrease VB 0 1 1 O
PDT NNP 0 1 UNK O
activity NN 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Drugs NNS 0 1 2 O
that WDT 0 0 12 O
decrease VBP 0 1 1 O
clotting VBG 1 1 14 O
vasoconstriction NN 0 1 UNK O
or CC 0 0 12 O
platelet NN 0 1 14 O
aggregation NN 0 1 UNK O
e.g. FW 0 0 UNK O
thromboxane NN 0 1 UNK O
A9 NNP 0 1 UNK O
inhibitors NNS 1 1 14 O
could MD 0 0 12 O
decrease VB 0 1 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
PDT NNP 0 1 UNK O
. . 0 0 12 O

Glucocorticoid NNP 0 1 UNK B-Group
hormones NNS 1 1 13 O
given VBN 1 1 12 O
before IN 0 1 12 O
or CC 0 0 12 O
concomitant NN 0 1 6 O
with IN 0 0 12 O
PDT NNP 0 1 UNK O
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
. . 0 0 12 O

Preclinical NNP 0 1 UNK O
data NNS 0 1 1 O
also RB 0 0 12 O
suggest VBP 0 1 1 O
that IN 0 0 12 O
tissue NN 0 1 6 O
ischemia NN 0 1 8 O
allopurinol NN 0 1 13 B-Drug
calcium NN 0 1 14 B-Group
channel NN 0 1 1 I-Group
blockers NNS 1 0 6 I-Group
and CC 0 0 12 O
some DT 0 0 12 O
prostaglandin JJ 0 1 13 O
synthesis NN 0 1 UNK O
inhibitors NNS 1 1 14 O
could MD 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
PHOTOFRIN NNP 0 1 UNK O
PDT NNP 0 1 UNK O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
Infergen NNP 0 1 UNK B-Brand
. . 0 0 12 O

Infergen NN 0 1 UNK B-Brand
should MD 0 0 12 O
be VB 0 0 12 O
used VBN 1 1 12 O
cautiously RB 0 0 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
are VBP 1 0 12 O
receiving VBG 1 1 1 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
are VBP 1 0 12 O
known VBN 1 1 12 O
to TO 0 0 12 O
cause VB 0 1 12 O
myelosuppression NN 0 1 8 O
or CC 0 0 12 O
with IN 0 0 12 O
agents NNS 1 1 1 O
known VBN 1 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
metabolized VBN 1 1 UNK O
via IN 0 0 1 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P NNP 0 1 2 O
- : 0 0 2 O
9 CD 0 0 2 O
pathway.9 NN 0 1 UNK O
Patients NNS 0 1 7 O
taking VBG 1 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
this DT 0 0 12 O
pathway NN 0 1 UNK O
should MD 0 0 12 O
be VB 0 0 12 O
monitored VBN 1 1 1 O
closely RB 0 0 1 O
for IN 0 0 12 O
changes NNS 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
therapeutic JJ 0 1 6 O
and CC 0 0 12 O
/ JJ 0 0 2 O
or CC 0 0 12 O
toxic JJ 0 1 1 O
levels NNS 1 1 1 O
of IN 0 0 12 O
concomitant NN 0 1 6 O
drugs NNS 1 1 6 O
. . 0 0 12 O

However RB 0 0 1 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Concomitant NNP 0 1 UNK O
glucocorticoid JJ 0 1 13 O
therapy NN 0 1 6 O
may MD 0 0 1 O
inhibit VB 0 1 13 O
the DT 0 0 12 O
response NN 0 1 1 O
to TO 0 0 12 O
Geref NNP 0 1 UNK B-Brand
. . 0 0 12 O
There EX 0 0 12 O
was VBD 1 0 12 O
no DT 0 0 12 O
evidence NN 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
controlled JJ 0 1 1 O
studies NNS 1 1 1 O
of IN 0 0 12 O
Geref NNP 0 1 UNK B-Brand
's POS 0 1 12 O
interaction NN 0 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBN 1 1 12 O
in IN 0 0 12 O
the DT 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
routine JJ 0 1 1 O
pediatric JJ 0 1 6 O
problems NNS 1 1 1 O
/ VBP 0 0 2 O
illnesses NNS 1 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNP 0 1 UNK O
Administration NNP 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
BEXXAR NNP 0 1 UNK B-Brand
therapeutic JJ 0 1 6 O
regimen NNS 0 1 6 O
may MD 0 0 1 O
result VB 0 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
development NN 0 1 1 O
of IN 0 0 12 O
human JJ 0 1 1 O
anti SYM 0 0 3 O
- : 0 0 2 O
murine NN 0 1 13 O
antibodies NNS 1 1 14 O
( ( 0 0 2 O
HAMA NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

The DT 0 0 2 O
presence NN 0 1 1 O
of IN 0 0 12 O
HAMA NNP 0 1 UNK O
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
accuracy NN 0 1 UNK O
of IN 0 0 12 O
the DT 0 0 12 O
results NNS 1 1 1 O
of IN 0 0 12 O
in IN 0 0 12 O
vitro NN 0 1 UNK O
and CC 0 0 12 O
in IN 0 0 12 O
vivo JJ 0 1 13 O
diagnostic JJ 0 1 6 O
tests NNS 1 1 1 O
and CC 0 0 12 O
may MD 0 0 1 O
affect VB 0 1 1 O
the DT 0 0 12 O
toxicity NN 0 1 6 O
profile NN 0 1 1 O
and CC 0 0 12 O
efficacy NN 0 1 UNK O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
agents NNS 1 1 1 O
that WDT 0 0 12 O
rely VBP 0 0 UNK O
on IN 0 0 12 O
murine NN 0 1 13 O
antibody NN 0 1 14 O
technology NN 0 1 13 O
. . 0 0 12 O

No DT 0 0 2 O
formal JJ 0 1 1 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
. . 0 0 12 O

Due JJ 0 1 2 O
to TO 0 0 12 O
the DT 0 0 12 O
frequent JJ 0 1 1 O
occurrence NN 0 1 1 O
of IN 0 0 12 O
severe JJ 0 1 6 O
and CC 0 0 12 O
prolonged JJ 0 1 6 O
thrombocytopenia NN 0 1 14 O
the DT 0 0 12 O
potential JJ 0 1 1 O
benefits NNS 1 1 1 O
of IN 0 0 12 O
medications NNS 1 1 6 O
that WDT 0 0 12 O
interfere VBP 0 1 UNK O
with IN 0 0 12 O
platelet NN 0 1 14 O
function NN 0 1 1 O
and CC 0 0 12 O
/ NN 0 0 2 O
or CC 0 0 12 O
anticoagulation NN 0 1 14 O
should MD 0 0 12 O
be VB 0 0 12 O
weighed VBN 1 0 12 O
against IN 0 0 12 O
the DT 0 0 12 O
potential NN 0 1 1 O
increased VBD 1 1 1 O
risk NN 0 1 1 O
of IN 0 0 12 O
bleeding NN 0 1 6 O
and CC 0 0 12 O
hemorrhage NN 0 1 6 O
. . 0 0 12 O

Therefore RB 0 0 1 O
warfarin NN 0 1 14 B-Drug
dose JJ 0 1 6 O
changes NNS 1 1 1 O
and CC 0 0 12 O
monitoring NN 0 1 1 O
for IN 0 0 12 O
the DT 0 0 12 O
effects NNS 1 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
on IN 0 0 12 O
blood NN 0 1 6 O
clotting NN 0 1 14 O
are VBP 1 0 12 O
necessary JJ 0 0 1 O
. . 0 0 12 O

Patients NNS 0 1 7 O
who WP 0 0 12 O
are VBP 1 0 12 O
HAMA NNP 0 1 UNK O
positive JJ 0 1 1 O
may MD 0 0 1 O
be VB 0 0 12 O
at IN 0 0 12 O
increased VBN 1 1 1 O
risk NN 0 1 1 O
for IN 0 0 12 O
serious JJ 0 1 12 O
allergic JJ 0 1 6 O
reactions NNS 1 1 1 O
and CC 0 0 12 O
other JJ 0 0 12 O
side NN 0 1 3 O
effects NNS 1 1 1 O
if IN 0 0 12 O
they PRP 0 0 12 O
undergo VBP 0 0 1 O
in IN 0 0 12 O
vivo NN 0 1 13 O
diagnostic JJ 0 1 6 O
testing NN 0 1 1 O
or CC 0 0 12 O
treatment NN 0 1 6 O
with IN 0 0 12 O
murine JJ 0 1 13 B-Group
monoclonal JJ 0 1 13 I-Group
antibodies NNS 1 1 14 I-Group
. . 0 0 12 O

Heparin NNP 0 1 0 B-Drug
should MD 0 0 12 O
not RB 0 1 12 O
be VB 0 0 12 O
included VBN 1 1 1 O
in IN 0 0 12 O
the DT 0 0 12 O
same JJ 0 1 12 O
syringe NN 0 1 3 O
as IN 1 0 12 O
Sodium NNP 0 1 14 B-Drug
Tetradecyl NNP 0 0 UNK I-Drug
Sulfate NNP 0 1 0 I-Drug
since IN 0 1 12 O
the DT 0 0 12 O
two CD 0 1 12 O
are VBP 1 0 12 O
incompatible JJ 0 1 13 O
. . 0 0 12 O

The DT 0 0 2 O
physician NN 0 1 6 O
must MD 0 0 12 O
use VB 0 1 1 O
judgment NN 0 1 UNK O
and CC 0 0 12 O
evaluate VB 0 1 1 O
any DT 0 0 12 O
patient NN 0 1 6 O
taking VBG 1 0 12 O
antiovulatory JJ 0 0 UNK O
drugs NNS 1 1 6 O
prior RB 0 1 1 O
to TO 0 0 12 O
initiating VBG 1 1 1 O
treatment NN 0 1 6 O
with IN 0 0 12 O
Sotradecol NNP 0 1 UNK B-Brand
. . 0 0 12 O

Interactions NNS 0 1 UNK O
for IN 0 0 12 O
Sodium NNP 0 1 14 B-Drug
Tetradecyl NNP 0 0 UNK I-Drug
Sulfate NNP 0 1 0 I-Drug
: : 0 0 2 O
No DT 0 0 2 O
well RB 0 1 12 O
- : 0 0 2 O
controlled VBN 1 1 1 O
studies NNS 1 1 1 O
have VBP 0 0 12 O
been VBN 1 0 12 O
performed VBN 1 1 1 O
on IN 0 0 12 O
patients NNS 1 1 6 O
taking VBG 1 0 12 O
antiovulatory JJ 0 0 UNK O
agents NNS 1 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
Trial NNP 0 1 2 O
9 CD 0 0 2 O
the DT 0 0 12 O
proportions NNS 1 1 UNK O
of IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
the DT 0 0 12 O
placebo NN 0 1 13 O
and CC 0 0 12 O
Synagis NNP 0 1 0 B-Brand
groups NNS 1 1 1 O
who WP 0 0 12 O
received VBD 1 1 12 O
routine JJ 0 1 1 O
childhood NN 0 1 12 O
vaccines NNS 1 1 6 B-Group
influenza VBP 0 1 6 B-Group
vaccine JJ 0 1 6 I-Group
bronchodilators NNS 1 1 14 B-Group
or CC 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
were VBD 1 0 12 O
similar JJ 0 1 1 O
and CC 0 0 12 O
no DT 0 0 12 O
incremental JJ 0 1 UNK O
increase NN 0 1 1 O
in IN 0 0 12 O
adverse JJ 0 0 1 O
reactions NNS 1 1 1 O
was VBD 1 0 12 O
observed VBN 1 1 1 O
among IN 0 0 12 O
patients NNS 1 1 6 O
receiving VBG 1 1 1 O
these DT 0 0 12 O
agents NNS 1 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
pharmacokinetic JJ 0 1 UNK O
profile NN 0 1 1 O
of IN 0 0 12 O
temazepam NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
appear VB 0 1 12 O
to TO 0 0 12 O
be VB 0 0 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
orally RB 0 1 14 O
administered VBN 1 1 1 O
cimetidine NN 0 1 13 B-Drug
dosed VBN 1 1 14 O
according VBG 1 1 1 O
to TO 0 0 12 O
labeling NN 0 1 UNK O
. . 0 0 12 O

TERAZOL $ 0 1 UNK B-Brand
9 CD 0 0 2 O
Vaginal NNP 0 1 7 O
Cream NNP 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
TERAZOL NNP 0 1 UNK B-Brand
9 CD 0 0 2 O
Vaginal NNP 0 1 7 O
Suppositories NNPS 0 1 UNK O
9 CD 0 0 2 O
mg VBD 0 1 0 O
The DT 0 0 2 O
therapeutic JJ 0 1 6 O
effect NN 0 1 1 O
of IN 0 0 12 O
these DT 0 0 12 O
products NNS 1 1 1 O
is VBZ 1 0 12 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
oral JJ 0 1 6 O
contraceptive JJ 0 1 13 B-Group
usage NN 0 1 UNK O
. . 0 0 12 O

TERAZOL $ 0 1 UNK B-Brand
9 CD 0 0 2 O
Vaginal NNP 0 1 7 O
Cream NNP 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
The DT 0 0 2 O
levels NNS 1 1 1 O
of IN 0 0 12 O
estradiol NN 0 1 13 B-Drug
( ( 0 0 2 O
E9 NNP 0 0 UNK O
) ) 0 0 2 O
and CC 0 0 12 O
progesterone NN 0 1 13 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
differ VB 0 0 UNK O
significantly RB 0 0 1 O
when WRB 0 0 12 O
9 CD 0 0 2 O
% NN 0 0 18 O
terconazole JJ 0 1 13 B-Drug
vaginal JJ 0 1 6 O
cream NN 0 1 3 O
was VBD 1 0 12 O
administered VBN 1 1 1 O
to TO 0 0 12 O
healthy JJ 0 1 12 O
female NN 0 1 12 O
volunteers NNS 1 1 UNK O
established VBN 1 1 1 O
on IN 0 0 12 O
a DT 0 0 12 O
low JJ 0 1 1 O
dose JJ 0 1 6 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
. . 0 0 12 O

Drug NNP 0 1 2 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
Macugen NNP 0 1 UNK B-Brand
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
as IN 1 0 12 O
yet RB 0 0 12 O
no DT 0 0 12 O
known VBN 1 1 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
but CC 0 0 12 O
further JJ 0 1 1 O
study NN 0 1 1 O
is VBZ 1 0 12 O
required VBN 1 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
data NN 0 1 1 O
are VBP 1 0 12 O
available JJ 0 1 1 O
regarding VBG 1 0 1 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
BILTRICIDE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

This DT 0 0 2 O
medicine NN 0 1 6 O
is VBZ 1 0 12 O
generally RB 0 0 1 O
safe JJ 0 0 12 O
with IN 0 0 12 O
other JJ 0 0 12 O
medications NNS 1 1 6 O
but CC 0 0 12 O
patient NN 0 1 6 O
should MD 0 0 12 O
consult VB 0 1 1 O
doctor NN 0 1 12 O
or CC 0 0 12 O
pharmacist NN 0 1 13 O
if IN 0 0 12 O
patient NN 0 1 6 O
is VBZ 1 0 12 O
taking VBG 1 0 12 O
a DT 0 0 12 O
blood NN 0 1 6 O
thinner NN 0 0 3 O
( ( 0 0 2 O
anticoagulant JJ 0 1 13 B-Group
) ) 0 0 2 O
cyclosporin NN 0 1 14 B-Drug
phenytoin NN 0 1 16 B-Drug
or CC 0 0 12 O
methotrexate NN 0 1 16 B-Drug
. . 0 0 12 O

Because IN 0 0 12 O
systemic JJ 0 1 6 O
exposure NN 0 1 1 O
to TO 0 0 12 O
Valstar NNP 0 1 UNK B-Brand
is VBZ 1 0 12 O
negligible JJ 0 1 UNK O
following VBG 1 1 1 O
intravesical JJ 0 1 UNK O
administration NN 0 1 1 O
the DT 0 0 12 O
potential JJ 0 1 1 O
for IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
is VBZ 1 0 12 O
low JJ 0 1 1 O
. . 0 0 12 O

Maternal NNP 0 1 7 O
sinus NN 0 1 6 O
bradycardia NN 0 1 8 O
with IN 0 0 12 O
abnormal JJ 0 1 6 O
atrioventricular JJ 0 0 8 O
rhythms NN 1 1 3 O
has VBZ 1 0 12 O
also RB 0 0 12 O
been VBN 1 0 12 O
noted VBN 1 0 1 O
when WRB 0 0 12 O
oxytocin NN 0 1 13 B-Drug
was VBD 1 0 12 O
used VBN 1 1 12 O
concomitantly RB 0 0 14 O
with IN 0 0 12 O
cyclopropane NN 0 1 UNK O
anesthesia NN 0 1 6 O
. . 0 0 12 O

Misoprostol NNP 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
exert VB 0 1 13 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effects NNS 1 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
absorption NN 0 1 1 O
blood NN 0 1 6 O
levels NNS 1 1 1 O
and CC 0 0 12 O
anti SYM 0 0 3 O
- : 0 0 2 O
platelet NN 0 1 14 O
effects NNS 1 1 1 O
of IN 0 0 12 O
therapeutic JJ 0 1 6 O
doses NNS 1 1 6 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
. . 0 0 12 O

9 CD 0 0 2 O

Pyrazinamide NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
ACETEST NNP 0 0 UNK O
and CC 0 0 12 O
KETOSTIX NNP 0 1 UNK O
urine JJ 0 1 6 O
tests NNS 1 1 1 O
to TO 0 0 12 O
produce VB 0 0 1 O
a DT 0 0 12 O
pink NN 0 1 3 O
- : 0 0 2 O
brown JJ 0 1 3 O
color NN 0 1 3 O
. . 0 0 12 O

Severe JJ 0 1 7 O
hypertension NN 0 1 6 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
reported VBN 1 1 1 O
when WRB 0 0 12 O
oxytocin NN 0 1 13 B-Drug
was VBD 1 0 12 O
given VBN 1 1 12 O
three CD 0 1 12 O
to TO 0 0 12 O
four CD 0 1 12 O
hours NNS 1 1 12 O
following VBG 1 1 1 O
prophylactic JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
vasoconstrictor NN 0 1 UNK B-Group
in IN 0 0 12 O
conjunction NN 0 1 1 O
with IN 0 0 12 O
caudal JJ 0 1 8 O
block NN 0 1 3 O
anesthesia NN 0 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
/ NNP 0 0 2 O
Laboratory NNP 0 1 2 O
Test NNP 0 1 2 O
Interactions NNS 0 1 UNK O
: : 0 0 2 O
Potential JJ 0 1 UNK O
interactions NNS 1 1 UNK O
between IN 0 0 12 O
ERTACZOTM NNP 0 0 UNK B-Brand
Cream NNP 0 1 2 O
9 CD 0 0 2 O
% NN 0 0 18 O
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
or CC 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
systematically RB 0 0 UNK O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Combined JJ 0 1 UNK O
usage NN 0 1 UNK O
of IN 0 0 12 O
MAO NNP 0 1 14 B-Group
inhibitors NNS 1 1 14 I-Group
should MD 0 0 12 O
be VB 0 0 12 O
avoided VBN 1 0 1 O

Cyclopropane NNP 0 1 UNK O
anesthesia NN 0 1 6 O
may MD 0 0 1 O
modify VB 0 1 UNK O
oxytocin RP 0 1 13 B-Drug
cardiovascular JJ 0 1 6 O
effects NNS 1 1 1 O
so RB 0 1 12 O
as IN 1 0 12 O
to TO 0 0 12 O
produce VB 0 0 1 O
unexpected JJ 0 1 12 O
results NNS 1 1 1 O
such JJ 0 0 1 O
as IN 1 0 12 O
hypotension NN 0 1 6 O
. . 0 0 12 O

thus RB 0 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
that WDT 0 0 12 O
inhibit VBP 0 1 13 O
induce VB 0 1 6 O
or CC 0 0 12 O
are VBP 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
those DT 0 0 12 O
enzymes NNS 1 1 14 O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

Olmesartan NNP 0 1 UNK B-Drug
medoxomil NN 0 0 16 I-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
and CC 0 0 12 O
has VBZ 1 0 12 O
no DT 0 0 12 O
effects NNS 1 1 1 O
on IN 0 0 12 O
P9 NNP 0 1 UNK O
enzymes NNS 1 1 14 O
; : 0 0 2 O

The DT 0 0 2 O
bioavailability NN 0 1 UNK O
of IN 0 0 12 O
olmesartan NN 0 1 16 B-Drug
was VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
altered VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
co NN 0 1 12 O
- : 0 0 2 O
administration NN 0 1 1 O
of IN 0 0 12 O
antacids NNS 1 1 14 B-Group
[ NNP 0 0 2 O
Al NNP 0 1 UNK O
( ( 0 0 2 O
OH NNP 0 1 UNK O
) ) 0 0 2 O
9 CD 0 0 2 O
/ JJ 0 0 2 O
Mg NNP 0 1 0 O
( ( 0 0 2 O
OH NNP 0 1 UNK O
) ) 0 0 2 O
9 CD 0 0 2 O
] NN 0 0 2 O
. . 0 0 12 O

No DT 0 0 2 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
were VBD 1 0 12 O
reported VBN 1 1 1 O
in IN 0 0 12 O
studies NNS 1 1 1 O
in IN 0 0 12 O
which WDT 0 0 12 O
olmesartan VBP 0 1 16 B-Drug
medoxomil NN 0 0 16 I-Drug
was VBD 1 0 12 O
co JJ 0 1 12 O
- : 0 0 2 O
administered VBN 1 1 1 O
with IN 0 0 12 O
digoxin NN 0 1 14 B-Drug
or CC 0 0 12 O
warfarin NN 0 1 14 B-Drug
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
. . 0 0 12 O

There EX 0 0 12 O
are VBP 1 0 12 O
so RB 0 1 12 O
far RB 0 1 12 O
no RB 0 0 12 O
reported JJ 0 1 1 O
adverse JJ 0 0 1 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
SAMe NNP 0 1 UNK B-Drug
and CC 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
dietary JJ 0 1 6 O
supplements NNS 1 1 6 O
or CC 0 0 12 O
foods NNS 1 1 1 O
. . 0 0 12 O

A DT 0 0 2 O
study NN 0 1 1 O
in IN 0 0 12 O
healthy JJ 0 1 12 O
volunteers NNS 1 1 UNK O
involving VBG 1 1 1 O
single JJ 0 1 12 O
- : 0 0 2 O
dose JJ 0 1 6 O
IV NNP 0 1 2 O
palonosetron NN 0 1 UNK B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg NN 0 1 0 O
) ) 0 0 2 O
and CC 0 0 12 O
steady JJ 0 1 1 O
state NN 0 1 1 O
oral JJ 0 1 6 O
metoclopramide NN 0 1 16 B-Drug
( ( 0 0 2 O
9 CD 0 0 2 O
mg RB 0 1 0 O
four CD 0 1 12 O
times NNS 1 1 12 O
daily RB 0 1 12 O
) ) 0 0 2 O
demonstrated VBD 1 0 1 O
no DT 0 0 12 O
significant JJ 0 1 1 O
pharmacokinetic JJ 0 1 UNK O
interaction NN 0 1 UNK O
. . 0 0 12 O

Remifentanil NNP 0 1 UNK B-Drug
clearance NN 0 1 16 O
is VBZ 1 0 12 O
not RB 0 1 12 O
altered VBN 1 1 1 O
by IN 0 0 12 O
concomitant JJ 0 1 6 O
administration NN 0 1 1 O
of IN 0 0 12 O
thiopental JJ 0 1 13 B-Drug
isoflurane NN 0 1 UNK B-Drug
propofol NN 0 1 14 B-Drug
or CC 0 0 12 O
temazepam NN 0 1 16 B-Drug
during IN 0 0 12 O
anesthesia NN 0 1 6 O
. . 0 0 12 O

In IN 0 0 2 O
animals NNS 1 1 12 O
the DT 0 0 12 O
duration NN 0 1 1 O
of IN 0 0 12 O
muscle NN 0 1 6 O
paralysis NN 0 1 6 O
from IN 0 0 12 O
succinylcholine NN 0 1 16 B-Drug
is VBZ 1 0 12 O
not RB 0 1 12 O
prolonged VBN 1 1 6 O
by IN 0 0 12 O
remifentanil NN 0 1 13 B-Drug
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
with IN 0 0 12 O
atracurium JJ 0 1 13 B-Drug
mivacurium NN 0 1 13 B-Drug
esmolol NN 0 1 13 B-Drug
echothiophate VBP 0 1 UNK B-Drug
neostigmine JJ 0 1 16 B-Drug
physostigmine NN 0 1 13 B-Drug
and CC 0 0 12 O
midazolam NN 0 1 16 B-Drug
revealed VBD 1 1 12 O
no DT 0 0 12 O
inhibition NN 0 1 13 O
of IN 0 0 12 O
remifentanil JJ 0 1 13 B-Drug
hydrolysis NN 0 1 UNK O
in IN 0 0 12 O
whole JJ 0 1 12 O
human JJ 0 1 1 O
blood NN 0 1 6 O
by IN 0 0 12 O
these DT 0 0 12 O
drugs NNS 1 1 6 O
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
with IN 0 0 12 O
VIGAMOX NNP 0 1 UNK B-Brand
solution NN 0 1 1 O
. . 0 0 12 O

In IN 0 0 2 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
indicate VBP 0 0 1 O
that IN 0 0 12 O
moxifloxacin NN 0 1 16 B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
inhibit VB 0 1 13 O
CYP9A9 NNP 0 0 UNK O
CYP9D9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
CYP9C9 NNP 0 0 UNK O
or CC 0 0 12 O
CYP9A9 NNP 0 0 UNK O
indicating VBG 1 0 1 O
that IN 0 0 12 O
moxifloxacin NN 0 1 16 B-Drug
is VBZ 1 0 12 O
unlikely JJ 0 1 12 O
to TO 0 0 12 O
alter VB 0 1 13 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
these DT 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
isozymes NNS 0 1 UNK O
. . 0 0 12 O

Clinical JJ 0 1 7 O
studies NNS 1 1 1 O
of IN 0 0 12 O
interactions NNS 1 1 UNK O
of IN 0 0 12 O
VIRAZOLE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
commonly RB 0 0 UNK O
used VBD 1 1 12 O
to TO 0 0 12 O
treat VB 0 1 12 O
infants NNS 1 1 6 O
with IN 0 0 12 O
RSV NNP 0 0 14 O
infections NNS 1 1 6 O
such JJ 0 0 1 O
as IN 1 0 12 O
digoxin NN 0 1 14 B-Drug
bronchodilators NNS 1 1 14 B-Group
other JJ 0 0 12 O
antiviral JJ 0 1 13 B-Group
agents NNS 1 1 1 I-Group
antibiotics NNS 1 1 6 B-Group
or CC 0 0 12 O
anti VB 0 0 3 B-Group
- : 0 0 2 O
metabolites NNS 1 1 UNK I-Group
have VBP 0 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

Interference NN 0 1 UNK O
by IN 0 0 12 O
VIRAZOLE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
laboratory NN 0 1 1 O
tests NNS 1 1 1 O
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
evaluated VBN 1 1 1 O
. . 0 0 12 O

Misoprostol NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
no DT 0 0 12 O
clinically RB 0 0 6 O
significant JJ 0 1 1 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
kinetics NNS 0 1 UNK O
of IN 0 0 12 O
diclofenac NN 0 1 16 B-Drug
or CC 0 0 12 O
ibuprofen NN 0 1 0 B-Drug
. . 0 0 12 O

Interactions NNS 0 1 UNK O
with IN 0 0 12 O
cylcopholsphamide JJ 0 0 UNK O
fludarabine NN 0 1 14 B-Drug
and CC 0 0 12 O
vidarabine NN 0 1 UNK B-Drug

In IN 0 0 2 O
vivo JJ 0 1 13 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
have VBP 0 0 12 O
suggested VBN 1 1 12 O
that IN 0 0 12 O
pioglitazone NN 0 1 16 B-Drug
may MD 0 0 1 O
be VB 0 0 12 O
a DT 0 0 12 O
weak JJ 0 1 12 O
inducer NN 0 1 UNK O
of IN 0 0 12 O
CYP NNP 0 1 UNK O
9 CD 0 0 2 O
isoform NN 0 1 UNK O
9A9 CD 0 0 UNK O
substrate NN 0 1 UNK O
. . 0 0 12 O

Pegaptanib NNP 0 1 UNK B-Drug
is VBZ 1 0 12 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
nucleases NNS 1 1 UNK O
and CC 0 0 12 O
is VBZ 1 0 12 O
generally RB 0 0 1 O
not RB 0 1 12 O
affected VBN 1 1 1 O
by IN 0 0 12 O
the DT 0 0 12 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
system NN 0 1 1 O
. . 0 0 12 O

lidocaine JJ 0 1 14 B-Drug
quinidine NN 0 1 16 B-Drug
; : 0 0 2 O

No DT 0 0 2 O
untoward JJ 0 0 6 O
clinical JJ 0 1 6 O
manifestations NNS 1 1 6 O
have VBP 0 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
in IN 0 0 12 O
limited JJ 0 1 1 O
experience NN 0 1 12 O
with IN 0 0 12 O
patients NNS 1 1 6 O
in IN 0 0 12 O
whom WP 0 0 12 O
PRIMACOR NNP 0 1 UNK B-Brand
was VBD 1 0 12 O
used VBN 1 1 12 O
concurrently RB 0 0 1 O
with IN 0 0 12 O
the DT 0 0 12 O
following VBG 1 1 1 O
drugs NNS 1 1 6 O
: : 0 0 2 O
digitalis NN 0 1 14 B-Group
glycosides NNS 1 1 13 I-Group
; : 0 0 2 O

- : 0 0 2 O
Increased VBD 0 1 7 O
action NN 0 1 13 O
of IN 0 0 12 O
oral JJ 0 1 6 O
anticoagulants NNS 1 1 13 B-Group
. . 0 0 12 O

- : 0 0 2 O
Decreased VBN 0 1 7 O
absorption NN 0 1 1 O
of IN 0 0 12 O
colestipol JJ 0 1 13 B-Drug
cholestyramine JJ 0 1 13 B-Drug
mineral NN 0 1 3 B-Drug
oil NN 0 1 3 I-Drug
and CC 0 0 12 O
sucralfate NN 0 1 0 B-Drug
. . 0 0 12 O

False NNP 0 1 UNK O
- : 0 0 2 O
positive JJ 0 1 1 O
tests NNS 1 1 1 O
may MD 0 0 1 O
occur VB 0 1 1 O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
hypertension NN 0 1 6 O
without IN 0 0 12 O
pheochromocytoma NN 0 1 UNK O
. . 0 0 12 O

Misoprostol NNP 0 1 UNK B-Drug
has VBZ 1 0 12 O
not RB 0 1 12 O
been VBN 1 0 12 O
shown VBN 1 1 1 O
to TO 0 0 12 O
interfere VB 0 1 UNK O
with IN 0 0 12 O
the DT 0 0 12 O
beneficial JJ 0 0 UNK O
effects NNS 1 1 1 O
of IN 0 0 12 O
aspirin NN 0 1 14 B-Brand
on IN 0 0 12 O
signs NNS 1 1 12 O
and CC 0 0 12 O
symptoms NNS 1 1 6 O
of IN 0 0 12 O
rheumatoid JJ 0 0 6 O
arthritis NN 0 1 6 O
. . 0 0 12 O

Diagnosis NN 0 1 7 O
of IN 0 0 12 O
pheochromocytoma NN 0 1 UNK O
- : 0 0 2 O
phentolamine NN 0 1 14 O
blocking VBG 1 1 UNK O
test NN 0 1 1 O
. . 0 0 12 O

The DT 0 0 2 O
test NN 0 1 1 O
is VBZ 1 0 12 O
most RBS 0 0 12 O
reliable JJ 0 1 UNK O
in IN 0 0 12 O
detecting VBG 1 1 UNK O
pheochromocytoma NN 0 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
sustained JJ 0 1 1 O
hypertension NN 0 1 6 O
and CC 0 0 12 O
least JJS 0 1 12 O
reliable JJ 0 1 UNK O
in IN 0 0 12 O
those DT 0 0 12 O
with IN 0 0 12 O
paroxysmal JJ 0 1 8 O
hypertension NN 0 1 6 O
. . 0 0 12 O

To TO 0 0 2 O
date NN 0 1 12 O
post NN 0 1 12 O
- : 0 0 2 O
marketing NN 0 1 UNK O
experience NN 0 1 12 O
has VBZ 1 0 12 O
not RB 0 1 12 O
revealed VBN 1 1 12 O
any DT 0 0 12 O
significant JJ 0 1 1 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
who WP 0 0 12 O
have VBP 0 0 12 O
received VBN 1 1 12 O
NOVANTRONE NNP 0 1 UNK B-Brand
for IN 0 0 12 O
treatment NN 0 1 6 O
of IN 0 0 12 O
cancer NN 0 1 6 O
. . 0 0 12 O

Mitoxantrone NN 0 1 UNK B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
are VBP 1 0 12 O
excreted VBN 1 1 UNK O
in IN 0 0 12 O
bile NN 0 1 6 O
and CC 0 0 12 O
urine NN 0 1 6 O
but CC 0 0 12 O
it PRP 0 0 12 O
is VBZ 1 0 12 O
not RB 0 1 12 O
known VBN 1 1 12 O
whether IN 0 0 12 O
the DT 0 0 12 O
metabolic NN 0 1 6 O
or CC 0 0 12 O
excretory NN 0 0 UNK O
pathways NNS 1 1 13 O
are VBP 1 0 12 O
saturable JJ 0 0 UNK O
may MD 0 0 1 O
be VB 0 0 12 O
inhibited VBN 1 1 13 O
or CC 0 0 12 O
induced VBN 1 1 6 O
or CC 0 0 12 O
if IN 0 0 12 O
mitoxantrone CD 0 1 13 B-Drug
and CC 0 0 12 O
its PRP$ 1 0 12 O
metabolites NNS 1 1 UNK O
undergo VBP 0 0 1 O
enterohepatic JJ 0 0 UNK O
circulation NN 0 1 1 O
. . 0 0 12 O

Following VBG 0 1 2 O
concurrent JJ 0 1 1 O
administration NN 0 1 1 O
of IN 0 0 12 O
NOVANTRONE NNP 0 1 UNK B-Brand
with IN 0 0 12 O
corticosteroids NNS 1 1 14 B-Group
no DT 0 0 12 O
evidence NN 0 1 1 O
of IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
has VBZ 1 0 12 O
been VBN 1 0 12 O
observed VBN 1 1 1 O
. . 0 0 12 O

Information NN 0 1 2 O
on IN 0 0 12 O
drug NN 0 1 1 O
interactions NNS 1 1 UNK O
in IN 0 0 12 O
patients NNS 1 1 6 O
with IN 0 0 12 O
multiple JJ 0 1 1 O
sclerosis NN 0 1 6 O
is VBZ 1 0 12 O
limited VBN 1 1 1 O
. . 0 0 12 O

Therefore RB 0 0 1 O
clinical JJ 0 1 6 O
interactions NNS 1 1 UNK O
with IN 0 0 12 O
drugs NNS 1 1 6 O
metabolized VBN 1 1 UNK O
by IN 0 0 12 O
human JJ 0 1 1 O
cytochrome NN 0 1 UNK O
P9 NNP 0 1 UNK O
isoenzymes NNS 0 1 14 O
are VBP 1 0 12 O
not RB 0 1 12 O
expected VBN 1 1 12 O
. . 0 0 12 O

An DT 0 0 2 O
additional JJ 0 1 1 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
showed VBD 1 1 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
rifaximin NN 0 1 16 B-Drug
on IN 0 0 12 O
the DT 0 0 12 O
presystemic JJ 0 0 UNK O
metabolism NN 0 1 16 O
of IN 0 0 12 O
an DT 0 0 12 O
oral JJ 0 1 6 O
contraceptive NN 0 1 13 B-Group
containing VBG 1 1 1 O
ethinyl JJ 0 0 13 B-Drug
estradiol NN 0 1 13 I-Drug
and CC 0 0 12 O
norgestimate NN 0 1 UNK B-Drug
. . 0 0 12 O

Drug NNP 0 1 2 O
- : 0 0 2 O
Drug NN 0 1 2 O
Interactions NNS 0 1 UNK O
Although IN 0 0 12 O
in IN 0 0 12 O
vitro JJ 0 1 UNK O
studies NNS 1 1 1 O
demonstrated VBD 1 0 1 O
the DT 0 0 12 O
potential NN 0 1 1 O
of IN 0 0 12 O
rifaximin NN 0 1 16 B-Drug
to TO 0 0 12 O
interact VB 0 0 UNK O
with IN 0 0 12 O
cytochrome JJ 0 1 UNK O
P9 NNP 0 1 UNK O
9A9 CD 0 0 UNK O
( ( 0 0 2 O
CYP9A9 NNP 0 0 UNK O
) ) 0 0 2 O
a DT 0 0 12 O
clinical JJ 0 1 6 O
drug NN 0 1 1 O
- : 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
study NN 0 1 1 O
demonstrated VBD 1 0 1 O
that IN 0 0 12 O
rifaximin NN 0 1 16 B-Drug
did VBD 1 0 12 O
not RB 0 1 12 O
significantly RB 0 0 1 O
affect VBP 0 1 1 O
the DT 0 0 12 O
pharmacokinetics NNS 0 1 UNK O
of IN 0 0 12 O
midazolam NN 0 1 16 B-Drug
either CC 0 1 12 O
presystemically RB 0 0 UNK O
or CC 0 0 12 O
systemically RB 0 0 UNK O
. . 0 0 12 O

Concomitant JJ 0 1 UNK O
administration NN 0 1 1 O
of IN 0 0 12 O
a DT 0 0 12 O
loop JJ 0 1 3 B-Group
diuretic NN 0 1 14 I-Group
had VBD 1 0 12 O
no DT 0 0 12 O
effect NN 0 1 1 O
on IN 0 0 12 O
the DT 0 0 12 O
calcium NN 0 1 14 O
- : 0 0 2 O
lowering VBG 1 1 UNK O
action NN 0 1 13 O
of IN 0 0 12 O
Aredia NNP 0 1 UNK B-Brand
. . 0 0 12 O

Oral JJ 0 1 2 O
contraceptives NNS 1 1 13 B-Group
containing VBG 1 1 1 O
estrogen NN 0 1 6 B-Drug
: : 0 0 2 O
tetracyclines NNS 1 1 13 B-Group
may MD 0 0 1 O
decrease VB 0 1 1 O
the DT 0 0 12 O
contraceptive JJ 0 1 13 O
effect NN 0 1 1 O
and CC 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
chance NN 0 1 12 O
of IN 0 0 12 O
unwanted JJ 0 0 13 O
pregnancy NN 0 1 6 O
. . 0 0 12 O

Not RB 0 1 2 O
compatible JJ 0 1 1 O
with IN 0 0 12 O
CNS NNP 0 1 6 B-Group
depressants NNS 1 0 13 I-Group
or CC 0 0 12 O
trycyclic JJ 0 0 UNK B-Group
antidepressants NNS 1 1 13 I-Group

The DT 0 0 2 O
contribution NN 0 1 1 O
of IN 0 0 12 O
vincristine JJ 0 1 16 B-Drug
sulfate NN 0 1 14 I-Drug
to TO 0 0 12 O
this DT 0 0 12 O
interaction NN 0 1 UNK O
is VBZ 1 0 12 O
not RB 0 1 12 O
certain JJ 0 1 1 O
. . 0 0 12 O

No DT 0 0 2 O
reported VBD 1 1 1 O
significant JJ 0 1 1 O
interactions NNS 1 1 UNK O

LUCENTIS NNP 0 1 UNK B-Brand
intravitreal NN 0 0 UNK O
injection NN 0 1 3 O
has VBZ 1 0 12 O
been VBN 1 0 12 O
used VBN 1 1 12 O
adjunctively RB 0 0 UNK O
with IN 0 0 12 O
verteporfin JJ 0 1 UNK B-Drug
photodynamic JJ 0 0 13 O
therapy NN 0 1 6 O
( ( 0 0 2 O
PDT NNP 0 1 UNK O
) ) 0 0 2 O
. . 0 0 12 O

May NNP 0 1 2 O
increase VB 0 1 1 O
the DT 0 0 12 O
effect NN 0 1 1 O
of IN 0 0 12 O
oral JJ 0 1 6 O
blood NN 0 1 6 B-Group
thinners NNS 1 1 14 I-Group
for IN 0 0 12 O
example NN 0 1 1 O
warfarin NN 0 1 14 B-Drug
( ( 0 0 2 O
Coumadin NNP 0 1 0 B-Brand
) ) 0 0 2 O
. . 0 0 12 O

Warfarin NN 0 1 0 B-Drug
: : 0 0 2 O
Sparfloxacin NN 0 1 UNK B-Drug
does VBZ 1 0 12 O
not RB 0 1 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
anti JJ 0 0 3 O
- : 0 0 2 O
coagulant JJ 0 1 UNK O
effect NN 0 1 1 O
of IN 0 0 12 O
warfarin NN 0 1 14 B-Drug
. . 0 0 12 O

Dosage NN 0 1 UNK O
adjustment NN 0 1 1 O
should MD 0 0 12 O
be VB 0 0 12 O
based VBN 1 1 1 O
on IN 0 0 12 O
serial JJ 0 1 1 O
blood NN 0 1 6 O
level NN 0 1 1 O
monitoring NN 0 1 1 O
. . 0 0 12 O

Also RB 0 0 2 O
see VB 0 1 12 O
CLINICAL NNP 0 1 11 O
PHARMACOLOGY NNP 0 1 UNK O

There EX 0 0 12 O
have VBP 0 0 12 O
been VBN 1 0 12 O
no DT 0 0 12 O
studies NNS 1 1 1 O
of IN 0 0 12 O
the DT 0 0 12 O
interaction NN 0 1 UNK O
of IN 0 0 12 O
methyl NN 0 0 13 B-Drug
aminolevulinate NN 0 1 UNK I-Drug
cream NN 0 1 3 O
with IN 0 0 12 O
any DT 0 0 12 O
other JJ 0 0 12 O
drugs NNS 1 1 6 O
including VBG 1 1 1 O
local JJ 0 1 12 O
anesthetics NNS 1 1 13 B-Group
. . 0 0 12 O

It PRP 0 0 12 O
is VBZ 1 0 12 O
possible JJ 0 1 1 O
that IN 0 0 12 O
concomitant JJ 0 1 6 O
use NN 0 1 1 O
of IN 0 0 12 O
other JJ 0 0 12 O
known VBN 1 1 12 O
photosensitizing VBG 1 1 UNK O
agents NNS 1 1 1 O
might MD 0 0 12 O
increase VB 0 1 1 O
the DT 0 0 12 O
photosensitivity NN 0 1 UNK O
reaction NN 0 1 1 O
of IN 0 0 12 O
actinic JJ 0 1 13 O
keratoses NNS 0 1 UNK O
treated VBN 1 1 1 O
with IN 0 0 12 O
methyl NN 0 0 13 B-Drug
aminolevulinate NN 0 1 UNK I-Drug
cream NN 0 1 3 O
. . 0 0 12 O

No DT 0 0 2 O
drug NN 0 1 1 O
interaction NN 0 1 UNK O
studies NNS 1 1 1 O
were VBD 1 0 12 O
conducted VBN 1 1 1 O
. . 0 0 12 O

